FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to pharmaceutical industry, namely to a composition for reducing obesity in humans, treating hypercholesterolemia in humans, achieving body weight reduction, body weight and waist circumference to maintain normal systemic lipid levels. Composition containing ethyl acetate fraction of methanol extract of Cyperus rotundus rhizomes, normalized to total content of stilbenes more than 3 %, for reduction of obesity in people. Composition containing ethyl acetate fraction of methanol extract of Cyperus rotundus rhizomes, normalized to total content of stilbenes more than 3 %, for treating hypercholesterinemia in humans. Use of the composition to achieve body weight reduction, body weight index and waist circumference. Use of the composition for maintaining normal systemic lipid levels by achieving effects (a) reducing systemic levels of total cholesterol, low-density lipoproteins (LDL), very low-density lipoproteins (VLDL) and serum triglycerides and (b) high systemic levels of high-density lipoproteins (HDL).
EFFECT: compositions described above are effective for reducing obesity in humans, treating hypercholesterolemia in humans, achieving body weight reduction, body weight and waist circumference to maintain normal systemic lipid levels.
10 cl, 18 tbl
Title | Year | Author | Number |
---|---|---|---|
CALEBIN A FOR HEPATIC STEATOSIS | 2015 |
|
RU2643297C2 |
COMPOSITION FOR ALLEVIATING, PREVENTING, OR TREATING BONE DISEASES OR METABOLIC DISEASES, CONTAINING A NEW STRAIN OF LACTOBACILLUS SAKEI CVL-001 AND A CULTURE MEDIUM THEREOF | 2020 |
|
RU2782361C1 |
DAIRY PRODUCT WITH REDUCED CHOLESTEROL CONTENT FOR APPLICATION AS MEDICATION | 2010 |
|
RU2546283C2 |
BETA-LACTAM COMPOUNDS OR THEIR SALTS FOR USE IN LONG-TERM PREVENTION OR TREATMENT OF DISORDERS OF GLUCOSE METABOLISM | 2020 |
|
RU2811476C2 |
COMPOSITION FOR STIMULATING OSTEOGENESIS AND MAINTAINING THE HEALTH OF BONES | 2002 |
|
RU2314717C2 |
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NON-ALCOHOLIC STEATOHEPATITIS | 2019 |
|
RU2765101C1 |
FODDER COMPOSITION FOR CONTROLLING BODY WEIGHT AND PREVENTING OBESITY AND OBESITY-ACCOMPANYING DISEASES IN DOMESTIC ANIMALS | 2002 |
|
RU2313228C2 |
HEPATOPROTECTIVE AGENT | 2003 |
|
RU2244553C1 |
PEPTIDE WITH ANTI-OBESITY AND ANTIDIABETIC EFFICACY AND USE THEREOF | 2017 |
|
RU2721426C1 |
ADIPOSITY RISK REDUCTION | 2010 |
|
RU2559646C2 |
Authors
Dates
2019-06-13—Published
2015-12-14—Filed